Senescent cells: SASP, accumulation, and ageing

In VascularVita longevity work, the aim is not to reverse chronological age. The aim is to protect the years in which a person can walk, decide, and sustain daily life — healthspan. Ageing is not reduced to a single test. Cellular and molecular decline, organ systems, a person’s intrinsic capacity, and function in daily life are read as one chain. Management rests on that reading: clarify the picture, reduce risk, deliver indicated treatment, and monitor.

At the cellular scale, one of the antagonistic sources in this chain is cellular senescence: the cell becomes a senescent cell. In López-Otín and colleagues’ framework of the hallmarks of aging, this response is protective in the short term and harmful when it accumulates. Damage to the genome, telomeres, and mitochondria can feed this pathway; this article opens how the cell stops dividing and keeps secreting. All nine hallmarks appear in the nine hallmarks of ageing; the programme is set out in the ageing stages and in individual assessment.

Senescent cell: useful in the short term, harmful when accumulated — schematic
A senescent cell is first a brake; when it accumulates, the SASP harms tissue.

What is a senescent cell?

A senescent cell permanently stops dividing but does not die at once. This state differs from apoptosis: the cell remains in the tissue and can continue to secrete. Triggers include DNA damage, telomere stress, oxidant load, oncogene activation, and certain metabolic disturbances. The common pathway is often the DNA damage response (DDR); the p53 / p21 and p16INK4a / Rb axes halt the cell cycle.

In the short term, this pause is tumour-suppressive: it limits expansion of a damaged genome. It can also play a temporary role in wound repair. The problem is that clearance and immune surveillance weaken with age. Senescent cells accumulate in tissue; as numbers rise, a useful “brake” becomes a harmful microenvironment (López-Otín 2023).

From damage to SASP: the senescent-cell accumulation cycle — schematic
Damage → cell-cycle arrest → SASP → inflammation and tissue disruption; accumulation feeds the cycle.

What is the SASP, and what does it do to tissue?

Accumulated senescent cells produce the senescence-associated secretory phenotype (SASP). This secretion includes cytokines, chemokines, growth factors, and matrix enzymes. The result is sterile inflammation, matrix remodeling, stress in neighbouring cells, and suppression of the stem-cell niche. The SASP thus links directly to stem cell exhaustion and intercellular communication; its inflammatory side overlaps inflammaging (Coppé et al., 2010).

Mitochondrial stress and the SASP can reinforce each other: energy impairment feeds the senescent-cell pathway; secretion also strains the mitochondrial milieu (Miwa et al., 2022). In a longevity reading, senescent-cell accumulation is not a single “cell score”; the echo is sought at tissue and function level.

Clinical face: fibrosis, joint, vessel

Clinical faces intersect idiopathic pulmonary fibrosis, osteoarthritis, diabetic kidney disease, atherosclerotic plaques, and some ocular complications. These are organ-specific disease pathways; they are not an “anti-ageing diagnosis.” The World Health Organization defines healthy ageing not as the absence of disease but as the preservation of functional ability; the same line is developed in our article on healthspan.

In longevity management, a single “senescent-cell score” does not assign a stage. Walking, grip strength, pain–mobility limitation, and daily independence are functional proxies. With organ involvement, the relevant specialty pathway follows the guideline.

What can be done?

The most mature levers are exercise and metabolic balance. Movement and sound nutrition help reduce SASP load and the inflammatory base; sleep supports the same network. This line intersects the articles on nutrient sensing and mitochondria.

In research, senolytics (candidates that selectively clear senescent cells; e.g., dasatinib + quercetin, fisetin) and senomorphics (approaches that suppress the SASP) are studied. Small human studies exist; early signals have been reported in diabetic kidney disease (Hickson et al., 2019). There is no general longevity indication. In local disease indications — for example, some ocular studies — the clinical research pathway is separate.

Senescent-cell management: prevention, disease pathway, and monitoring — schematic
Management: prevention (exercise, metabolic balance), specialty care in disease, monitoring by function.

What is done in management?

In the VascularVita approach, senescent-cell accumulation is addressed in three concrete steps.

First is prevention. Regular movement, sound nutrition, metabolic risk control, and sleep help limit SASP accumulation. The aim is not to “erase” a laboratory score; it is to delay inflammation and loss of function.

Second is disease-guided treatment. In fibrosis, joint, kidney, vascular, or ocular involvement, treatment follows the relevant guideline. Longevity screening reads ICOPE domains, frailty, and daily function together; it does not assign a stage from a single molecular “senescent-cell score.”

Third is monitoring over time. Senescent-cell secretion links to inflammation and the stem-cell niche. That is why attention is not limited to a single laboratory result. The same person’s walking, grip strength, mobility capacity, and independence are reassessed at defined intervals. The flow is on the individual assessment and ageing stages pages.

Summary

Cellular senescence is an antagonistic hallmark of ageing defined by conversion of the cell into a senescent cell. It is protective in the short term; when it accumulates, the SASP disrupts tissue and affects the stem-cell niche and intercellular communication. The most mature intervention is exercise, sound nutrition, and the metabolic base. Senolytics and senomorphics are under research. In VascularVita longevity management, this hallmark is addressed through prevention, indicated treatment, and function-focused monitoring.

References

  1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. doi:10.1016/j.cell.2013.05.039 · PMC3836174
  2. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243–278. doi:10.1016/j.cell.2022.11.001
  3. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118. doi:10.1146/annurev-pathol-121808-102144 · PMC2885946
  4. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics dasatinib and quercetin in diabetic kidney disease. EBioMedicine. 2019;47:446–456. doi:10.1016/j.ebiom.2019.08.069
  5. Miwa S, Kashyap S, Chini E, von Zglinicki T. Mitochondrial dysfunction in cell senescence and aging. J Clin Invest. 2022;132(13):e158447. doi:10.1172/JCI158447
  6. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709–713. doi:10.1016/j.cell.2014.10.039 · PMC4852871
  7. World Health Organization. World report on ageing and health. Geneva: WHO; 2015. who.int
  8. Cesari M, Araujo de Carvalho I, Amuthavalli Thiyagarajan J, et al. Evidence for the domains of the WHO’s Integrated Care for Older People (ICOPE). J Gerontol A Biol Sci Med Sci. 2018;73(12):1653–1660. doi:10.1093/gerona/gly011
  9. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–M156. doi:10.1093/gerona/56.3.m146

Related articles

← All articles

WhatsApp